Pfizer and Seagen have announced an agreement under which Pfizer will acquire Seagen for $229 in cash per share, valued at nearly $43 billion.
Pfizer is aiming that Seagen's expertise in Antibody-Drug Conjugates (ADCs) can strengthen Pfizer's oncology portfolio. Further, it is estimated that Seagen will add $10 billion in revenues by 2030. In 2023, the expected revenues from Seagen were $2.2 billion. Pfizer Oncology's portfolio has 24 approved therapies generating $12.1 billion in revenues.
Seagen's currently approved therapies include Adcetris, Padcev, Tivdak, and Tukysa. It further has eleven new molecular entities in the pipeline.
Sanofi has announced its intention to acquire Provention Bio, a U.S.-based biopharmaceutical company, for $2.9 billion. The acquisition will add Provention Bio's first-in-class therapy in type 1 diabetes, Tzield (teplizumab), to Sanofi's portfolio. Tzield was approved in the US last year as the first and only therapy to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients aged eight years and older with stage 2 T1D.
Sanofi's stated that the acquisition of Provention Bio aligns with the company's strategic shift towards developing products that have a unique profile in treating immune-mediated diseases and disease-modifying therapies, especially in areas with high unmet needs. Additionally, the acquisition is consistent with Sanofi's expertise in diabetes.
Sanofi announced that it would commence a cash tender offer to acquire Provention Bio's shares for $25.0 per share in cash, valued at approximately 2.9 billion.
With the acquisition, AstraZeneca will get access to aldosterone synthase inhibitor baxdrostat.
Baxdrostat is in Phase 2 for hyperaldosteronism and hypertension.
AstraZeneca announced that it would acquire a US-based clinical-stage biopharmaceutical company, CinCor Pharma, developing novel treatments for resistant and uncontrolled hypertension and chronic kidney disease.
With the acquisition, AstraZeneca aims to strengthen its cardiorenal portfolio with baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for resistant hypertension.
For this acquisition, AstraZeneca offered to pay $26 per share, followed by $10 per share upon successful regulatory submission of baxdrostat. The upfront payment represents a value of $1.3 billion. With the regulatory submission, the transaction value can reach $1.8 billion.